Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plantago lanceolata pollen, derived from the English or Ribwort plantain weed, is a significant source of airborne allergens that cause seasonal allergic diseases such as rhinoconjunctivitis and asthma during the summer. [1] Its allergenic properties stem from various proteins, with the glycoprotein Pla l 1 being the major allergen and an indicative marker for genuine sensitization. [0] Another identified allergen is the profilin Pla l 2, a panallergen that can cause cross-reactivity. [1] Due to the presence of homologous proteins, sensitization to Plantago lanceolata is often complicated by cross-reactivity with other common pollens like grass, birch, and ash. [0] Extracts of Plantago lanceolata pollen are used clinically for both the diagnosis of allergies via skin prick tests and for treatment through specific allergen immunotherapy (AIT), which aims to desensitize the immune system. [1, 2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Plantago lanceolata pollen.